130 related articles for article (PubMed ID: 11145232)
1. Oral delivery of new heparin derivatives in rats.
Lee Y; Kim SH; Byun Y
Pharm Res; 2000 Oct; 17(10):1259-64. PubMed ID: 11145232
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
Lee Y; Nam JH; Shin HC; Byun Y
Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
[TBL] [Abstract][Full Text] [Related]
5. Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles.
Khatun Z; Nurunnabi M; Cho KJ; Lee YK
Carbohydr Polym; 2012 Nov; 90(4):1461-8. PubMed ID: 22944403
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of absorption of heparin-DOCA conjugates on the intestinal wall using a surface plasmon resonance.
Kim SK; Kim K; Lee S; Park K; Park JH; Kwon IC; Choi K; Kim CY; Byun Y
J Pharm Biomed Anal; 2005 Oct; 39(5):861-70. PubMed ID: 16143485
[TBL] [Abstract][Full Text] [Related]
7. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
8. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
9. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
10. Prevention effect of orally active heparin derivative on deep vein thrombosis.
Kim SK; Lee DY; Kim CY; Moon HT; Byun Y
Thromb Haemost; 2006 Aug; 96(2):149-53. PubMed ID: 16894457
[TBL] [Abstract][Full Text] [Related]
11. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates.
Kim SK; Lee EH; Vaishali B; Lee S; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2005 Jun; 105(1-2):32-42. PubMed ID: 15925422
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
[TBL] [Abstract][Full Text] [Related]
13. Prevention effect of orally active heparin conjugate on cancer-associated thrombosis.
Al-Hilal TA; Alam F; Park JW; Kim K; Kwon IC; Ryu GH; Byun Y
J Control Release; 2014 Dec; 195():155-61. PubMed ID: 24862320
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery.
Kim SK; Huh J; Kim SY; Byun Y; Lee DY; Moon HT
Bioconjug Chem; 2011 Jul; 22(7):1451-8. PubMed ID: 21627301
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits.
Jiao Y; Ubrich N; Marchand-Arvier M; Vigneron C; Hoffman M; Lecompte T; Maincent P
Circulation; 2002 Jan; 105(2):230-5. PubMed ID: 11790706
[TBL] [Abstract][Full Text] [Related]
17. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.
Al-Hilal TA; Park J; Alam F; Chung SW; Park JW; Kim K; Kwon IC; Kim IS; Kim SY; Byun Y
J Control Release; 2014 Feb; 175():17-24. PubMed ID: 24333628
[TBL] [Abstract][Full Text] [Related]
18. [Oral cavity delivery system of unfractionated and low molecular weight heparin].
Li D; Hou HM
Yao Xue Xue Bao; 2010 Oct; 45(10):1317-21. PubMed ID: 21348313
[TBL] [Abstract][Full Text] [Related]
19. Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP.
Leone-Bay A; Paton DR; Variano B; Leipold H; Rivera T; Miura-Fraboni J; Baughman RA; Santiago N
J Control Release; 1998 Jan; 50(1-3):41-9. PubMed ID: 9685871
[TBL] [Abstract][Full Text] [Related]
20. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
